COMP <GO>
EXP vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Eagle Materials Inc (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: EXP 9
— TMO 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: EXP
LAST: $183.64 (+0.99%) • MKT CAP: $5.58B
roic
14.50%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXP VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXP | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.30% | 41.00% | -12.70 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 14.50% | 9.30% | +5.20 | EXP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.9x | 30.4x | -22.50 | EXP | /valuation <GO> |
| Free Cash Flow Yield | 3.54% | 2.40% | +1.14 | EXP | /fcf-yield <GO> |
| Operating Margin | 22.40% | 17.40% | +5.00 | EXP | /operating-margins <GO> |
| Net Profit Margin | 18.40% | 15.10% | +3.30 | EXP | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | 3.90% | -1.80 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.58% | 0.24% | +0.34 | EXP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.26 | 4.50 | -1.24 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | EXP | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.2 | 59.1 | +3.08 | EXP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.94 | -0.07 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 36.3x | -24.00 | EXP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.58B | $262.22B | -$256.64B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXP REV | TMO REV | EXP GROSS % | TMO GROSS % | EXP FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.31B | $44.56B | 28.3% | 44.0% | $197.4M | $6.29B |
| FY 2024 | $2.26B | $42.88B | 29.8% | 44.0% | $353.3M | $7.27B |
| FY 2023 | $2.26B | $42.86B | 44.0% | 44.0% | $462.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXP // BETA 0.87
TMO // BETA 0.94